Clinical Trial Update: Lipid Efficacy of the Extended Release Niacin/Laropiprant Combination in Patients With Cardiovascular Disease [Phase 4]

View source ↗

Summary

Phase 4 trial update on the lipid-lowering efficacy of an extended-release niacin/laropiprant combination in cardiovascular disease; the study status is termina…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Dyslipidemias

Drugs mentioned

• niacin/laropiprant extended-release (niacin/laropiprant)

Snippet

Sponsor: Daniel A. Siniawski | Conditions: Coronary Artery Disease, Dyslipidemias | Phase 4 | Status: TERMINATED